1Kuhn M. Molecular physiology of natriuretic peptide signaling [J]. Basic Res Cardiol, 2004, 99(2): 76-82.
2Maric C, Zheng W, Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase [J]. Nephron Physiol, 2006, 103(3): 149-156.
3McMurray J J. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances [J]. Eur J Heart Fall, 2015, 17(3): 242-247.
4Packer M, Califf R M, Konstam M A, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) [J]. Circulation, 2002, 106(8): 920-926.
5Messerli F H, Nussberger J. Vasopeptidase inhibition and angio-oedema [J]. Lancet, 2000, 356(9230): 608-609.
6Cruden N L, Fox K A, Ludlam C A, et al. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition [J]. Hypertension, 2004, 44(6): 913-918.
7Hegde L G, Yu C, Renner T, et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat [J]. J Cardiovasc Pharmacol, 2011, 57(4): 495-504.
8David H, Bernhard W, Matthias L, et al. Process for preparing biaryl substituted 4-amino-butryric acid or derivertives thereof and their use in the production of NEP inhibitors [P]. WO: 2008031567, 2007-09-11.
9Li F, Erik G S, Allen S P, et al. Compounds containing S-N-valeryl-N-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionyl-amino)-2-methyl-pentanoic acid ethyl ester moieties and cations [P]. US: 20150057322, 2014-06-23.
10Gardner D G, Chen S, Glenn D J, et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension [J]. Hypertension, 2007, 49(3): 419-426.
